2.80

0.72% 0.02

After Hours: 2.80

Ovid Therapeutics Inc (OVID)

Overview News Price History Option Chain Financials Discussions Forecast

Ovid Therapeutics Inc stock is traded at $2.80, with a volume of 1.07M. It is up +0.72% in the last 24 hours and up +10.24% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Previous Close:

$2.78

Open:

$2.74

24h Volume:

1.07M

Relative Volume:

0.48

Market Cap:

$546.83M

Revenue:

$7.12M

Net Income/Loss:

$-24.17M

P/E Ratio:

-11.50

EPS:

-0.2434

Net Cash Flow:

$-41.95M

1W Performance:

+0.00%

1M Performance:

+10.24%

6M Performance:

+66.67%

1Y Performance:

+117.05%

1-Day Range:

$2.71

$2.825

1-Week Range:

$2.64

$2.87

52-Week Range:

$1.12

$3.105

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name

Ovid Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

212-776-4381

Address

441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY

Employee

Twitter

@OvidRx

Next Earnings Date

2026-08-12

Latest SEC Filings

OVID's Discussions on Twitter

Compare OVID vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OVID Ovid Therapeutics Inc	2.80	535.12M	7.12M	-24.17M	-41.95M	-0.2434
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-25	Initiated	Roth Capital	Buy
Nov-17-25	Initiated	Leerink Partners	Outperform
Oct-09-25	Initiated	Oppenheimer	Outperform
Aug-08-25	Resumed	B. Riley Securities	Buy
Jun-18-24	Downgrade	Oppenheimer	Outperform → Perform
Apr-30-24	Initiated	B. Riley Securities	Buy
Apr-29-24	Initiated	H.C. Wainwright	Buy
Apr-05-24	Initiated	Wedbush	Outperform
Dec-21-23	Initiated	BTIG Research	Buy
Oct-13-23	Initiated	Oppenheimer	Outperform
Apr-20-21	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-03-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-02-20	Downgrade	Citigroup	Buy → Neutral
Dec-02-20	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-19	Initiated	RBC Capital Mkts	Outperform
Apr-20-18	Initiated	Ladenburg Thalmann	Buy

View All

Ovid Therapeutics Inc Stock (OVID) Latest News

Sep 04, 2026

September Investor Conferences: Key Catalysts For OVID, Biomea, Nuvectis & More - rttnews.com

Sep 04, 2026

Sep 03, 2026

Ovid Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Sep 03, 2026

Aug 30, 2026

OVID Financials: Income Statement, Balance Sheet & Cash Flow | Ovid Therapeutics Inc - Stock Titan

Aug 30, 2026

Aug 24, 2026

Ovid Therapeutics (OVID) insider prepares new stock sale after recent August trades - Stock Titan

Aug 24, 2026

Aug 20, 2026

Balyasny Asset Management L.P. Adds to Ovid Therapeutics Inc (OV - GuruFocus

Aug 20, 2026